The National Institutes Of Health Spends More In 2020 Funding For Research On Chronic And Acute Pain In NIH ‘Pain Research Center’ To Try And Prevent Opioid Ad-diction In A COVID-19 Health Environment; Bioelectronic Relief That Treats Chronic Pain Is Offered By Electromedical Technologies, Inc. (OTCQB: EMED) Through Alter-native Devices To Opioid Addicting Pain Killer Pharmaceuticals
The National Institutes Of Health (NIH) has raised the stakes on chronic pain and possible treatment that leads to opioid addiction through pain killer pharmaceuticals. NIH awarded its ‘Pain Research Center’ additional funding through its Director’s Challenge Innovative Award program in 2020 as it seeks to focus research on chronic pain and its treatments in part to discover new therapies that are not opioid-addictive. Electromedical Technologies, Inc. (OTCQB: EMED) offers a solution in treating chronic and acute pain without using opioid-addictive pharmaceutical drugs. Bioelectronic relief to chronic pain is available through its growing line of FDA-cleared WellnessPro Plus™ devices that deliver electrotherapy treatment.
The chronic pain treatment market has drawn intense interest from media companies. stockmarketpress.com features specialized coverage of related stocks such as Electromedical Technologies, Inc. (OTCQB: EMED), Medtronic PLC (NYSE: MDT), Nevro Corp. (NYSE: NVRO), Axsome Therapeutics, Inc. (NASDAQ: AXSM). GlaxoSmithKline (NYSE: GSK), Abbott Laboratories (NYSE: TBA), Eli Lilly (NYSE: LLY), Boston Scientific Corporation (NYSE: BSX), Novartis AG (NYSE: NVS), Johnson & Johnson (NYSE: JNJ) and Bristol-Myers Squibb (NYSE: BMY).
The National Institutes Of Health Spends More In 2020 Funding For Research On Chronic And Acute Pain In NIH ‘Pain Research Center’ To Try And Prevent Opioid Addiction In A COVID-19 Health Environment; Bioelectronic Relief That Treats Chronic Pain Is Offered By Electromedical Technologies, Inc. (OTCQB: EMED) Through Alternative Devices To Opioid Addicting Pain Killer Pharmaceuticals
In 2020, the NIH is spending even more on funding for chronic pain research, opioid misuse disorders, personalized therapies to manage pain, the efficacy of non-opioid treatments and predicting how individual patients will respond to therapies and outcomes. In addition to regular budgeted funding for 2020, the ‘Pain Research Center’ has also been named a recent of additional pain research funding through a special ‘Director’s Challenge Innovation’ award.
The extra funding into chronic pain is a two-year investment. The National Institutes Of Health Spends More In 2020 Funding For Research On Chronic And Acute Pain In NIH ‘Pain Research Center’ To Try And Prevent Opioid Addiction In A COVID-19 Health Environment; Bioelectronic Relief That Treats Chronic Pain Is Offered By Electromedical Technologies, Inc. (OTCQB: EMED) Through Alternative Devices To Opioid Addicting Pain Killer Pharmaceuticals.
The NIH said, “Chronic pain affects millions of people, lacks effective treatments and and is a primary driver of opioid misuse disorders.” The National Institutes Of Health Spends More In 2020 Funding For Research On Chronic And Acute Pain In NIH ‘Pain Research Center’ To Try And Prevent Opioid Addiction In A COVID-19 Health Environment; Bioelectronic Relief That Treats Chronic Pain Is Offered By Electromedical Technologies, Inc. (OTCQB: EMED) Through Alternative Devices To Opioid Addicting Pain Killer Pharmaceuticals.
The FDA-cleared WellnessPro Plus™ and anticipated for 2021 the WellnessPro® Pod are non-invasive and avoid side-effects such as opioid addiction
Electromedical Technologies, Inc. (OTCQB: EMED) has developed devices such as the FDA-cleared WellnessPro Plus™ and anticipated for 2021 the WellnessPro® Pod. These are non-invasive devices which avoid side-effects such as opioid addiction. The National Institutes Of Health Spends More In 2020 Funding For Research On Chronic And Acute Pain In NIH ‘Pain Research Center’ To Try And Prevent Opioid Addiction In A COVID-19 Health Environment; Bioelectronic Relief That Treats Chronic Pain Is Offered By Electromedical Technologies, Inc. (OTCQB: EMED) Through Alternative Devices To Opioid Addicting Pain Killer Pharmaceuticals.
Bioelectronic Treatment Offers Pain Relief
As the NIH intensifies its funding of research studies into chronic and acute pain and its treatment side effect of opioid-addicting pain killer pharmaceuticals, Electromedical Technologies, Inc. (OTCQB: EMED) is a leader in the field of addressing acute and chronic pain and sees itself at the forefront of future medicine. Opioid addiction from pain-killer pharmaceuticals, is only made worse by COVID-19. The global pandemic causes patients with chronic pain to limit or avoid physical physician visits, postpone surgical treatments and limit out-of-home mobility.
StreetInsider.com describes how electrotherapy and bioelectronic treatments can be helpful in treating chronic and acute pain without addictive drugs. It terms the Electromedical Technologies, Inc. (OTCQB: EMED) devices as in the forefront of the future of medicine. Matthew Wolfson, founder and CEO of EMED, has pursued collaboration with universities and schools on chronic pain research and certification training that offers a ‘Bioelectronics Therapist and Master Device Technician.’ The goal is to educate students and physicians the techniques and benefits that use drug free application for treatment of chronic, acute and intractable pain.
Pain Treatment Market Is Projected By Research To Reach $151.7 Billion Globally By 2030
A new research study by The Centers For Disease Control And Prevention (CDC) finds that greater than 20% of American adults suffer from chronic pain and high-impact chronic pain, sometimes resulting in opioid dependence. The COVID-19 pandemic, a recent study by Prescient & Strategic Intelligence reports, only exacerbates these numbers and helps drive the chronic pain treatment market globally by a 6.5% CAGR rate to $151.7 Billion by 2030 from $77.8 Billion in 2019.
EMED Plans To Study The Effects Of Electro-Modulation On The Human Body
Electromedical Technologies, Inc. (OTCQB: EMED) offers a growing line of devices that deliver electrotherapy treatment for chronic and acute pain. Next year, the Company anticipates bringing to market its WellnessPro® Pod. The Company is collaborating with numerous universities and schools to research the field of bioelectronics. It is seeking to develop a program to study the effects of electro-modulation on the human body, especially cell signaling and virus assembly and immune responses.
Source: Stock Market Press
Join Stock Market Press’ newsletter for the latest in IPO, market commentary and company profiles.
Stock Market Press is a financial news company that delivers up to date stock news, introduces private and public companies to a wide audience of investors, consumers, journalists and the general public via social media and a rapidly expanding network.
Contact:
Stock Market Press
110 Wall St.
New York, NY 10005 info@stockmarketpress.com Safe Harbor Statement:
Statements in this news release may be ”forward-looking statements.” Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release and Stock Market Press undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release.
See Stock Market Press disclaimer: https://stockmarketpress.com/disclaimer/ SOURCE: Stock Market Press
